These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37123934)

  • 1. Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report.
    Huang H; Zhang Y; Chen Z; Zeng X; Hu Z; Yang C
    Heliyon; 2023 Apr; 9(4):e15157. PubMed ID: 37123934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downstaging guided neoadjuvant strategy shift and bladder preservation in locally advanced bladder cancer: A case report.
    Du G; Jiang Z; Qu W; Zhang J; Zheng S; Liu Y; Zhou A; Shi H; Shou J
    Heliyon; 2024 Mar; 10(6):e27685. PubMed ID: 38515680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder.
    Sung HH; Kim H; Kim R; Kim CK; Kwon GY; Park W; Song W; Jeong BC; Park SH
    Investig Clin Urol; 2022 Mar; 63(2):168-174. PubMed ID: 35244990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
    Meleis L; Moore R; Inman BA; Harrison MR
    J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review.
    Qi X; Guo J; Zhou X; Sun L; Lin J; Huang Z; Chen H; Lin L
    Heliyon; 2022 Sep; 8(9):e10581. PubMed ID: 36185140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
    Murasawa H; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Iwabuchi I; Ogasawara M; Kawaguchi T
    Int J Clin Oncol; 2017 Feb; 22(1):159-165. PubMed ID: 27534866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series.
    Wang Z; Wang Y; Wang S; Ran Q; Peng S; Zhang Y; Zhang J; Zhang D; Wang L; Lan W; Liu Q; Jiang J
    Ann Med Surg (Lond); 2024 Jan; 86(1):245-251. PubMed ID: 38222740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer.
    Pal SK; Ruel NH; Wilson TG; Yuh BE
    Clin Genitourin Cancer; 2012 Dec; 10(4):246-50. PubMed ID: 22981208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.
    Baras AS; Gandhi N; Munari E; Faraj S; Shultz L; Marchionni L; Schoenberg M; Hahn N; Hoque MO; Berman D; Bivalacqua TJ; Netto G
    PLoS One; 2015; 10(7):e0131245. PubMed ID: 26230923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer.
    Dai L; Jin X; Wang L; Wang H; Yan Z; Wang G; Liang B; Huang F; Luo Y; Chen T; Wang Q
    Onco Targets Ther; 2022; 15():267-275. PubMed ID: 35321517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.
    Aydin AM; Cheriyan SK; Reich R; Hajiran A; Peyton CC; Zemp L; Yu A; Li R; Poch MA; Spiess PE; Jain R; Zhang J; Sexton WJ; Gilbert SM
    Urol Oncol; 2022 Oct; 40(10):453.e19-453.e26. PubMed ID: 35811208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder.
    Kim H; Jeong BC; Hong J; Kwon GY; Kim CK; Park W; Pyo H; Song W; Sung HH; Hong JY; Park SH
    Cancer Res Treat; 2023 Apr; 55(2):636-642. PubMed ID: 36228654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
    North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR
    J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: Successful treatment of advanced urothelial carcinoma with trophoblastic differentiation using Tislelizumab and Disitamab vedotin.
    Han Y; Zhou Y; Wu Z; Liu L; Han C
    Heliyon; 2024 Oct; 10(19):e38518. PubMed ID: 39397900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial.
    Anari F; O'Neill J; Choi W; Chen DYT; Haseebuddin M; Kutikov A; Dulaimi E; Alpaugh RK; Devarajan K; Greenberg RE; Bilusic M; Wong YN; Viterbo R; Hoffman-Censits JH; Lallas CD; Trabulsi EJ; Smaldone M; Geynisman DM; Zibelman M; Lin J; Kelly WK; Uzzo R; McConkey D; Plimack ER
    Eur Urol Oncol; 2018 May; 1(1):54-60. PubMed ID: 30420974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncological Outcomes of Neoadjuvant Gemcitabine plus Carboplatin versus Gemcitabine plus Cisplatin in Locally Advanced Bladder Cancer: A Retrospective Analysis.
    Mofid B; Razzaghdoust A; Ghajari M; Basiri A; Fattahi MR; Houshyari M; Jafari A; Taghizadeh-Hesary F
    Urol J; 2022 Nov; 19(5):371-378. PubMed ID: 35246833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.
    Montazeri K; Dranitsaris G; Thomas JD; Curran C; Preston MA; Steele GS; Kilbridge KL; Mantia C; Ravi P; McGregor BA; Mossanen M; Sonpavde G
    Urol Oncol; 2021 Dec; 39(12):834.e1-834.e7. PubMed ID: 34162500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.